Xian Qian

Xian Qian


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
JHJuan He
Juan He
ZYZhitao YANG
Zhitao YANG
XQXian Qian
Xian Qian
BZBing Zhao
Bing Zhao
EMEnqiang Mao
Enqiang Mao
XBXiaolan Bian
Xiaolan Bian
Background: Using standard vancomycin dosage in critically ill patients might lead to therapy failure and worse patient outcomes, augmented renal clearance (ARC) may be the leading risk factor. In this study, we comprehensively investigated the pharmacokinetics-pharmacodynamics (PK-PD) of vancomycin in critically ill patients with ARC, hoping to explore the precise and accurate dose adjustment method for vancomycin. Methods: All critically ill patients tested for steady-state trough vancomycin serum concentrations during the recent 6 years in a tertiary level hospital were collected retrospectively and divided into ARC and non-ARC groups, respectively, according to creatinine clearance (CLcr). Serum vancomycin concentrations were measured by the fluorescence polarization immunoassay method. PK-PD parameters of vancomycin were recorded or calculated. The desired daily dose successful in achieving the lower target trough levels (10 mg/L) of vancomycin were investigated correspondingly. Results: A total of 280 vancomycin concentrations were eligible for analysis. The ARC group (n=139) contained more male patients (64.7%) with average age and CLcr of 40 years old (P<0.05) and 180.8 mL/min (P<0.001), respectively. Those patients exhibited higher clearance (CL) and lower trough serum concentrations than the non-ARC patients under comparable daily doses of vancomycin. All the ICU patients demonstrated lower AUC24h values than the target level of 400 µg·h/mL, and this value showed a lower trend in the ARC group than the non-ARC group (232.9 vs. 316.2 µg·h/mL). Subtherapeutic trough concentrations of vancomycin (<10.0 mg/L) were observed in 77.7% and 68.8% of the ARC and non-ARC patients (P<0.05). The proportion of patients with a trough concentration of 10–15 and 15–20 mg/L was 17.9% and 4.3%, respectively, in the ARC group and 24.8% and 2.8%, respectively, in the non-ARC group., a daily dose of 46.0 and 35.5 mg/kg of vancomycin is needed, respectively, in the ARC and non-ARC group to achieve a target trough concentration of 10 mg/L. Conclusions: A higher dose of vancomycin is needed in critically ill patients, especially those with ARC, and appropriate TDM-guided dose adjustment should be considered to achieve the targeted therapeutic range and to provide dosing guidance for this: patient population.

5 January 2023 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
XZXuhong Zhang
Xuhong Zhang
TCTao Chen
Tao Chen
XQXian Qian
Xian Qian
XHXiaojin He
Xiaojin He
Background. Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are both autoimmune diseases, and they often occur together in clinical practice, but the pathogenesis is unclear. This study is aimed at identifying the hub genes and explore the related immune molecular mechanisms between AS and IBD by bioinformatics analysis. Methods. From the public Gene Expression Omnibus (GEO) database, the AS and IBD datasets (GSE73754, GSE59071, GSE25101, and GSE36807) were obtained. The immune cell infiltration in the peripheral blood tissues of GSE73754 and GSE59071 was assessed using the CIBERSORT algorithm. Then, we used the Weighted Gene Coexpression Network Analysis (WGCNA) to identify the Differentially Expressed Genes (DEGs) related to AS and IBD. Then, the immune genes from the ImmPort database intersected with the DEGs to obtain hub genes. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyzed the functional correlation of hub genes. Then, hub genes were verified in GSE25101 and GSE36807. The clusterProfiler software and Gene Set Enrichment Analysis (GSEA) were used to conduct functional enrichment and pathway enrichment studies. Finally, the diagnostic efficacy was assessed using Receiver Operating Characteristic (ROC) curve analysis. Results. The analysis of immune characteristics showed that both AS and IBD were related to immunity, and neutrophils were positively correlated in both diseases. Nine coexpressed genes, including FCGRT, S100A11, IFNGR1, NFKBIZ, JAK2, LYN, PLAUR, ADM, and IL1RN, were linked to immune cells. The GO and KEGG analyses results showed that enrichment analysis was mainly related to cell transport and migration. Finally, the ROC curve was verified with the validation set, and it was found that PLAUR has clinical diagnostic significance and the most excellent specificity and sensitivity, respectively. Conclusions. PLAUR (uPAR) is a promising biomarker and will be an underlying genetic biomarker for diagnosing AS comorbid IBD. Inflammation and immunological modulation mediated by neutrophil infiltration were important in the development of AS and IBD and may be diagnostic and therapeutic targets.

1 January 2024 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
XZXuhong Zhang
Xuhong Zhang
LZLamei Zhou
Lamei Zhou
XQXian Qian
Xian Qian
Background. Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are prevalent autoimmune disorders that often co‐occur, posing significant treatment challenges. This investigation adopts a multidisciplinary strategy, integrating bioinformatics, network pharmacology, molecular docking, and Mendelian randomization, to elucidate the relationship between AS and IBD and to investigate the potential mechanisms of traditional Chinese medicine formulations, represented by Qiangji Jianpi (QJJP) decoction, in treating these comorbid conditions. Methods. We utilized databases to pinpoint common targets among AS, IBD, and QJJP decoction’s active compounds through intersection analysis. Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, we mapped a network in Cytoscape, isolating critical targets. Molecular docking with AutoDock validated the affinity between targets and compounds. ROC analysis and dataset validation assessed diagnostic performance, while Gene Set Enrichment Analysis (GSEA) offered pathway insights. Mendelian randomization explored the AS‐IBD causal relationship. Results. Screening identified 105 targets for QJJP decoction, 414 for AS, and 2420 for IBD, with 85 overlapping. These targets predominantly participate in organismal responses and DNA transcription factor binding, with a significant cellular presence in the endoplasmic reticulum and vesicle lumen. Molecular docking, facilitated by Cytoscape, confirmed IL1A, IFNG, TGFB1, and EDN1 as critical targets, with IFNG demonstrating diagnostic potential through GEO dataset validation. The integration of GSEA with network pharmacology highlighted the therapeutic significance of the relaxin, osteoclast differentiation, HIF‐1, and AGE‐RAGE signaling pathways in QJJP decoction’s action. Mendelian randomization analysis indicated a positive causal relationship between IBD and AS, pinpointing rs2193041 as a key SNP influencing IFNG. Conclusion. Based on the principle of “treating different diseases with the same method” in traditional Chinese medicine theory, we explored the intricate mechanisms through which QJJP decoction addresses AS and IBD comorbidity. Our research spotlighted the pivotal role of the IFNG gene. IFNG emerges not only as a key therapeutic target but also assumes significance as a potential diagnostic biomarker through its genetic underpinnings. This investigation establishes a solid base for subsequent experimental inquiries. Our findings introduce novel approaches for incorporating traditional Chinese medicine into the treatment of AS‐IBD comorbidity, setting the stage for groundbreaking research directions.

5 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
XQXian Qian
Xian Qian
LZLamei Zhou
Lamei Zhou
XQXian Qian
Xian Qian
Background: Previous studies have observed a significant association between immune cell traits and Ankylosing spondylitis (AS); however, a causal relationship has not been established. Therefore, we conducted this bidirectional Mendelian randomization study to comprehensively evaluate the intricate interactions between 731 immune cell traitsand AS, aiming to uncover potential causal relationships while enhancing our understanding of disease development. Methods: We retrieved extensive genome-wide association study (GWAS) data from two reputable sources, the IEU open GWAS database and the FinnGen studies, renowned for their extensive genetic information. We performed a bidirectional Mendelian randomization study to investigate the causal relationship between 731 immune cell traits and Ankylosing Spondylitis (AS). Our analysis utilized the Inverse Variance Weighted (IVW) method, along with MR-Egger, Weighted Median, and Weighted Mode. We assessed associations between 731 immune cell traits and AS using odds ratios (OR) and 95% confidence intervals (CI). Finally, we performed tests for horizontal pleiotropy, heterogeneity, and conducted a leave-one-out sensitivity analysis to validate our results. Results: Our research has established that 10 distinct immune cell types significantly contribute to the development of Ankylosing Spondylitis (AS). We identified 3 types of monocytes, 1 type of T cell, 1 type of B cell, and 1 type of granulocyte as risk factors for AS. In contrast, a different group of immune cells, including 1 type of monocyte, 2 types of T cells, and 1 type of B cell, appears to offer protection against the disease. Concerning the onset of AS, its impact on immune traits is evident in the varied expressions across 41 T cell subgroups: 16 subtypes show high expression, while 25 demonstrate low expression. Similarly, in B cells, 3 subtypes are highly expressed, and 4 subtypes are lowly expressed. Likewise, variations in expression were observed in lymphocytes and monocytes, with 3 types of each showing high and low expression, respectively. Moreover, our study reveals a bidirectional causal relationship between the expression of CX3CR1 on CD14+ CD16- monocytes and on monocytes generally, and the occurrence of AS. Conclusion: The goal of this research is dedicated to exploring the bidirectional causal relationship between immune cells traits and Ankylosing Spondylitis (AS). It aims to not only offer new avenues for unraveling the biological mechanisms of AS but also to guide clinical research towards novel investigative directions and to provide fresh clues for the development of new therapeutic approaches.